Michael K. Schultz, PhD

Portrait
Associate Professor of Radiology - Division of Nuclear Medicine
Associate Professor of Radiation Oncology
Associate Professor of Pediatrics
Associate Professor of Chemistry

Contact Information

Primary Office: B180 ML
500 Newton Road
Iowa City, IA 52242
319-335-8017

319-384-4454

Education

BA, Russian Language, University of South Florida, Department of Linguistics
MS, Marine Chemistry, Florida State University, Department of Oceanography
PhD, Chemical Oceanography, Florida State University

Fellow, Graduate Researcher/Radiochemist (Predoctoral PhD Fellowship), National Institute of Standards and Technology, Gaithersburg, MD
Postdoctoral Fellow, Radiochemist (Postdoctoral, Targeted Radionuclide Therapy for Cancer Research), National Institute of Standards and Technology, Nuclear Medicine Program. Gaithersburg, MD

Education/Training Program Affiliations

Free Radical and Radiation Biology Graduate Program, Interdisciplinary Graduate Program in Human Toxicology, Medical Scientist Training Program

Research Summary

Michael K. Schultz, PhD, is an Associate Professor of Radiology, Pediatrics, Chemistry and Radiation Oncology (Free Radical and Radiation Biology Program) at The University of Iowa. Dr. Schultz’s lab focuses on tumor cell biology, radiation biology, peptide based ligand development, and radiochemistry for the development of image-guided radionuclide based therapies for cancer. The lab focuses on NETs, related pediatric brain tumors, and metastatic melanoma. With underlying support from the NET SPORE (PI M. Sue O’Dorisio MD PhD). Dr. Schultz’s lab is laying a foundation for alpha particle targeted therapy for these cancers through three basic initiatives supported by the NET SPORE and other NIH/NCI funding. (1) Image-guided peptide theranostic development; (2) Enhanced dosimetry modeling focused on alpha particle interactions in the tumor microenvironment; and (3) Radiopharmaceutical production automation for theranostic agents. The lab is focused on the theranostic pair of radionuclides 203Pb for SPECT imaging and 212Pb for alpha + beta particle therapy for cancer. (4) Oxidative metabolism and the role of mitochondrial ROS metabolism in the acquisition of resistance to cancer chemotherapies with a focus on the relationships between ROS metabolism, ER stress, autophagic flux, and acquisition of resistance.

For synopses of these projects and more information about Dr. Schultz's research and academic activities, please visit the Schultz Lab website.